Portal de investigación
A Phase 2/3, randomized, double-blind, placebocontrolled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD).
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
GLAXOSMITHKLINE RESEARCH & DEV. LTD
Cita
A Phase 2/3, randomized, double-blind, placebocontrolled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD). (218224). GLAXOSMITHKLINE RESEARCH & DEV. LTD. 2023IP:JOSÉ ANDRÉS ROMÁN IVORRA.